Login to Your Account

AAN Roundup

Wednesday, April 13, 2011
Neuralstem Inc., of Rockville, Md., reported interim data from the first nine patients in a Phase I trial of human spinal cord stem cells in amyotrophic lateral sclerosis, showing that all nine patients remain alive and there were no unresolved serious adverse reactions related to surgery. Of the three ambulatory patients who were treated, all remain ambulatory, with no serious adverse events secondary to surgery. The study is designed to enroll up to 18 patients and, if approved by the FDA and the safety monitoring board, the study will progress to cervical transplantation this summer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription